PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions

被引:48
作者
Brooks, Benjamin Rix [1 ]
Crumpacker, David [2 ]
Fellus, Jonathan [3 ]
Kantor, Daniel [4 ]
Kaye, Randall E. [5 ]
机构
[1] Univ N Carolina, Sch Med, Carolinas Med Ctr, Charlotte, NC 28223 USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Int Brain Res Fdn, Flanders, NJ USA
[4] Neurologique, Ponte Vedra Beach, FL USA
[5] Avanir Pharmaceut Inc, Aliso Viejo, CA USA
来源
PLOS ONE | 2013年 / 8卷 / 08期
关键词
EMOTIONAL EXPRESSION DISORDER; PATHOLOGICAL LAUGHTER; POSTSTROKE DEPRESSION; INCONTINENCE; EPIDEMIOLOGY; SCLEROSIS; DISEASE; STROKE; ALS; PATHOPHYSIOLOGY;
D O I
10.1371/journal.pone.0072232
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Pseudobulbar affect (PBA) is a neurological condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying, which can be socially disabling. Although PBA occurs secondary to many neurological conditions, with an estimated United States (US) prevalence of up to 2 million persons, it is thought to be under-recognized and undertreated. The PBA Registry Series (PRISM) was established to provide additional PBA symptom prevalence data in a large, representative US sample of patients with neurological conditions known to be associated with PBA. Methods: Participating clinicians were asked to enroll >= 20 consenting patients with any of 6 conditions: Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease (PD), stroke, or traumatic brain injury (TBI). Patients (or their caregivers) completed the Center for Neurologic Study-Lability Scale (CNS-LS) and an 11-point scale measuring impact of the neurological condition on the patient's quality of life (QOL). Presence of PBA symptoms was defined as a CNS-LS score >= 13. Demographic data and current use of antidepressant or antipsychotic medications were also recorded. Results: PRISM enrolled 5290 patients. More than one third of patients (n = 1944; 36.7%) had a CNS-LS score >= 13, suggesting PBA symptoms. The mean (SD) score measuring impact of neurological condition on QOL was significantly higher (worse) in patients with CNS-LS >= 13 vs,13 (6.7 [2.5] vs. 4.7 [3.1], respectively; P<0.0001 two-sample t-test). A greater percentage of patients with CNS-LS >= 13 versus <13 were using antidepressant/antipsychotic medications (53.0% vs 35.4%, respectively; P<0.0001, chi-square test). Conclusions: Data from PRISM, the largest clinic-based study to assess PBA symptom prevalence, showed that PBA symptoms were common among patients with diverse neurological conditions. Higher CNS-LS scores were associated with impaired QOL and greater use of antipsychotic/antidepressant medications. These data underscore a need for greater awareness, recognition, and diagnosis of PBA.
引用
收藏
页数:8
相关论文
共 60 条
  • [1] [Anonymous], EUR J NEUROL
  • [2] [Anonymous], NEUROLOGY S1
  • [3] [Anonymous], MULT SCLER
  • [4] Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554
  • [5] Baron-Cohen S, 1998, NATURE, V392, P459, DOI 10.1038/33076
  • [6] Psychological associations with emotionalism after stroke
    Calvert, T
    Knapp, P
    House, A
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 65 (06) : 928 - 929
  • [7] CAROSCIO JT, 1987, NEUROL CLIN, V5, P1
  • [8] Epidemiology of ALS in Italy A 10-year prospective population-based study
    Chio, A.
    Mora, G.
    Calvo, A.
    Mazzini, L.
    Bottacchi, E.
    Mutani, R.
    [J]. NEUROLOGY, 2009, 72 (08) : 725 - 731
  • [9] Poststroke depression and emotional incontinence Factors related to acute and subacute stages
    Choi-Kwon, S.
    Han, K.
    Choi, S.
    Suh, M.
    Kim, Y. -J.
    Song, H.
    Cho, K. -H.
    Nah, H. -W.
    Kwon, S. U.
    Kang, D. -W.
    Kim, J. S.
    [J]. NEUROLOGY, 2012, 78 (15) : 1130 - 1137
  • [10] Pseudobulbar Affect: Burden of Illness in the USA
    Colamonico, Jennifer
    Formella, Andrea
    Bradley, Walter
    [J]. ADVANCES IN THERAPY, 2012, 29 (09) : 775 - 798